McNicoll, Lewis & Vlak Reiterates Vivus Buy, $16 PT

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

McNicoll, Lewis & Vlak reiterated its Vivus (NASDAQ: VVUS) Buy rating and $16 price target in a research report published today.In the report, McNicoll, Lewis & Vlak states, " Today, VVUS announced data from the 47th European Association for the Study of Diabetes (EASD), which highlighted the long-term benefits of Qnexa treatment in metabolically-impaired patients with pre-diabetes, diabetes, and metabolic syndrome."Shares of Vivus were trading at $8.81 at the time of posting, down 0.79% from Thursday's market close.

27% profit every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!